Systemic antibody response to diarrheagenic Escherichia coli and LPS O111, O157 and O55 in healthy Brazilian adults

Scandinavian Journal of Immunology

Volumn 64, Issue 6, 2006, Pages 661-667

  Zapata Quintanilla, L B ^a   Palmeira, P ^b   Tino De Franco, M ^a   Amaral, J A ^a   Carbonare, C B ^b   Carbonare, S B ^a  

^a INSTITUTO BUTANTAN   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL ANTIGEN; BACTERIUM LIPOPOLYSACCHARIDE; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; VIRULENCE FACTOR;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATION; BLOOD SAMPLING; BRAZIL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIARRHEAGENIC ESCHERICHIA COLI; ENTEROHEMORRHAGIC ESCHERICHIA COLI; ENZYME LINKED IMMUNOSORBENT ASSAY; GRAM NEGATIVE BACTERIUM; HUMAN; IMMUNOREACTIVITY; NORMAL HUMAN; PRIORITY JOURNAL;

ADULT; ANTIBODIES, BACTERIAL; BRAZIL; CROSS REACTIONS; DIARRHEA; ESCHERICHIA COLI; ESCHERICHIA COLI O157; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LIPOPOLYSACCHARIDES; SEROEPIDEMIOLOGIC STUDIES;

EID: 33750813778     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/j.1365-3083.2006.01848.x     Document Type: Article

References (40)

1. Nataro JP, Kaper JP. Diarrheiogenic Escherichia coli. Clin Microbiol 1998;11:142-201.
2. Paton JC, Paton AW. Pathogenesis and diagnosis of Shiga toxin-producing Escherichia coli infections. Clin Microbiol Rev 1998;11:450-79.
3. Irino K, Vaz TM, Kato MA et al. O157:H7 Shiga toxin-producing Escherichia coli strains associated with sporadic cases of diarrhea in São Paulo, Brazil. Emerg Infect Dis 2002;8:446-7.
4. Vaz, TM, Irino K, Kato MA et al. Virulence properties and characteristic of Shiga toxin-producing Escherichia coli in São Paulo, from 1976 through 1999. J Clin Microbiol 2004;42:903-5.
5. Guth BEC, De Souza RL, Vaz TM, Irino K. First Shiga toxin-producing Escherichia coli isolate from a patient with hemolytic uremic syndrome, Brazil. Emerg Infect Dis 2002;8:535-6.
6. Cerqueira AM, Guth BEC, Joaquim RM, Andrade JR. High occurrence of Shiga toxin-producing Escherichia coli (STEC) in healthy cattle in Rio de Janeiro State, Brazil. Vet Microbiol 1999;70:111-21.
7. Leomil L, Aidar-Ugrinovich L, Guth BE et al. Frequency of Shiga toxin-producing Escherichia coli (STEC) isolated among diarrheic and non-diarrheic calves in Brazil. Vet Microbiol 2003;97:103-9.
8. Moreira CN, Pereira MA, Brod CS, Rodriguez DP, Carvalhal JB, Aleixo JÁ. Shiga toxin-producing Escherichia coli (STEC) isolated from healthy dairy cattle in Southern Brazil. Vet Microbiol 2003;93:179-83.
9. Cerqueira AMF, Tibana A, Guth BEC. High occurrence of Shiga-like toxin-producing strains among diarrheagenic Escherichia coli isolated from raw beef products in Rio de Janeiro City, Brazil. J Food Protection 1997;60:177-80.
10. Guth BE, Chinen I, Miliwebsky E et al. Serotypes and Shiga toxin phenotypes among Escherichia coli isolated from animals and food in Argentina and Brazil. Vet Microbiol 2003;92:335-49.
11. Kaper JB, Nataro JP, Mobley HL. Pathogenic Escherichia coli. Nat Rev Microbiol 2004;2:123-40.
12. Chart H, Jenkins C. Serodiagnosis of infection with verocytotoxin- producing Escherichia coli. J Appl Microbiol 1999;86:569-75.
13. Chart H, Perry NT. The serological response to verocytotoxigenic Escherichia coli in patients with haemolytic uraemic syndrome. J Appl Microbiol 2004;38:351-4.
14. Chart H, Rowe B. Improved detection of infection by Escherichia coli O157 in patients whit haemolitic uremic syndrome by means of IgA antibodies to lipoposysaccharide. J Infect 1992;24:257-61.
15. Greatorex JS, Thorne GM. Humoral immune responses to shiga-like toxins and Escherichia coli O157 lipoposysaccharide in haemolitic-uremic symdrome patients and healthy subjects. J Clin Microbiol 1994;32:1172-8.
16. Carbonare CB, Carbonare SB, Carneiro-Sampaio MMS. Early acquisition of serum and saliva antibodies reactive to enteropathogenic Escherichia coli (EPEC) virulence-associated proteins by infant living in na endemic area. Pediatr Allergy Immunol 2003;14:222-8.
17. Câmara LMC, Carbonare SB, Silva MLM, Carneiro-Sampaio MMS. Inhibition of enterophatogenic Escherichia coli (EPEC) adhesion to HeLa cells by human colostrums: detection of specific SIgA related to EPEC outer membrane proteins. Int Arch Allergy Immunol 1994;152:307-10.
18. Carbonare SB, Silva MLM, Palmeira P, Carneiro-Sampaio MMS. Human colostrum IgA antibodies reacting to enteropathogenic Escherichia coli (EPEC) antigens and their persistence in the faeces of breast-infant. J Diarrhoeal Dis 1997;15:53-8.
19. Delneri MT, Carbonare SB, Silva MLM, Palmeira P, Carneiro-Sampaio MMS. Inhibition of enterophatogenic Escherichia coli adhesion to HEp-2 cells by colostrums and milk from mothers delivering-low-birth weight neonates. Eur J Pediatric 1997;156:493-8.
20. Fernandes RM, Carbonare SB, Carneiro-Sampaio MMS, Trabulsi LR. Inhibition of enteroaggregative Escherichia coli adhesion to HEp-2 cells by secretory IgA from human colostrums. Pediatr Infect Dis J 2001;20:272-8.
21. Loureiro I, Frankel G, Adu-Bobie J, Dougan G, Trabulsi LR, Carneiro-Sampaio MMS. Human colostrums contain IgA antibodies reactive to enteropathogenic Escherichia coli virulence-associated proteins: intimin, BfpA, EspA and EspB. J Pediatr Gastroenterol Nutr 1998;27:166-71.
22. Sanches MA, Keller R, Hartland EL et al. Human colostrums and serum contain antibodies reactive to the intimina-binding region of the enterophatogenic Escherichia coli translocated intimin receptor. J Pediatr Gastroenterol Nutr 2000;30:73-7.
23. Palmeira P, Carbonare SB, Amaral JA, Tino-De-Franco M, Carneiro-Sampaio MMS. Colostrum from healthy Brazilian women inhibits adhesion and contains IgA antibodies reactivity with Shiga toxin-producing Escherichia coli. Eur J Pediatr 2005;164:37-43.
24. Carbonare SB, Silva MLM, Trabulsi LR, Carneiro-Sampaio MMS. Inhibition of HEp-2 cell invasion by Enteroinvasive Escherichia coli by human colostrum: detection of specific IgA related to invasion plasmid antigens. Int Arch Allergy Immunol 1995;108:113-8.
25. Fomsgaard A. Antibodies to lipoposysaccharides: some diagnostic and protective aspect. APMIS 1990;98 (Suppl.):5-38.
26. Nagao AT, Friedland-DelNero D, Arslanian C, Carneiro-Sampaio MMS. Elevated levels and different repertoire profile of colostral anti-LPS antibodies may have a significant role in compensating newborn immunity. Scand J Immunol 2001;53:602-9.
27. Chart H, Scotland SM, Rowe B. Serum antibodies to Escherichia coli serotype O157:H7 in patients whit haemolitic uremic syndrome. J Clin Microbiol 1989;27:285-90.
28. Ludwig K, Bitzan M, Zimmermann S, Kloth M, Ruder H, Muller-Wiefel DE. Immune response to non-O157 vero toxin-producing Escherichia coli in patients with hemolytic uremic syndrome. J Infect Dis 1996;174:1028-39.
29. Nagao AT, Martinez VC, Vieira VS, Takano AO, Costa-Carvalho BT, Carneiro-Sampaio MMS. Placental transfer of IgG subclass antibodies anti purified Escherichia coli LPS O16, O6 and O111. Scand J Immunol 1998;47:609-14.
30. Voss E, Paton AW, Manning PA, Paton JC. Molecular analysis of Shiga toxigenic Escherichia coli O111:H- proteins which react with sera from patients with hemolytic-uremic syndrome. Infect Immun 1998;66:1467-72.
31. Navarro A, Eslava C, Hernandez U et al. Antibody responses to Escherichia coli O157 and other lipopolysaccharides in healthy children and adults. Clin Diagn Lab Immunol 2003;10:797-801.
32. Amor K, Heinrichs DE, Fridich E, Ziebell K, Johnson RP, Whitfield C. Distribution of core oligosaccharide types in lipopolysaccharides from Escherichia coli. Infect Immun 2000;68:1116-24.
33. Wick LM, Qi W, Lacher DW, Whittam TS. Evolution of genomic content in the stepwise emergence of Escherichia coli O157:H7. J Bacteriol 2005;187:1783-91.
34. Gibb AP, Barclay GR, Poxton IR, Di Padova F. Frequencies of lipopolysaccharide core types among clinical isolates of Escherichia coli defined with monoclonal antibodies. J Infect Dis 1992;166:1051-7.
35. Currie CG, McCallum K, Poxton IR. Mucosal and systemic antibody responses to the lipopolysaccharide of Escherichia coli O157 in health and disease. J Med Microbiol 2001;50:345-54.
36. Ludwig K, Sarkim V, Bitzan M et al. Shiga toxin-producing Escherichia coli infection and antibodies against Stx2 and Stx1 in household contacts of children with enteropathic hemolytic-uremic syndrome. J Clin Microbiol 2002;40:1773-82.
37. Agin TS, Wolf MK. Identification of family of intimins common to Escherichia coli causing attaching-effacing lesion in rabbits, humans and swine. Infect Immun 1997;65:320-6.
38. Nakazato G, Gyles C, Ziebell K et al. Attaching and effacing Escherichia coli isolated from dogs in Brazil: characteristics and serotypic relationship to human enteropathogenic E. coli (EPEC). Vet Microbiol 2004;101:269-77.
39. Beutin L, Geier D, Zimmermann S, Aleksic S, Gillespie HA, Whittam TS. Epidemiological relatedness and clonal types of natural populations of Escherichia coli strains producing Shiga toxin in separate populations of cattle and sheep. Appl Environ Microbiol 1997;63:2175-80.
40. Hornitzki MA, Vanselow BA, Walker K et al. Virulence properties and serotypes of Shiga toxin-producing Escherichia coli from healthy Australian cattle. Appl Evirom Microbiol 2002;68:6439-45.